Clinical relevance of advances in genetics and pharmacogenetics of IBD.
暂无分享,去创建一个
[1] Laurent Beaugerie,et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. , 2004, Gastroenterology.
[2] K. Peters,et al. CARD15 and Crohn's disease , 2004, Journal of gastroenterology and hepatology.
[3] Judy H. Cho,et al. MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. , 2003, American journal of human genetics.
[4] T. Ahmad,et al. The contribution of human leucocyte antigen complex genes to disease phenotype in ulcerative colitis. , 2003, Tissue antigens.
[5] B. Bonaz,et al. Drug interaction between infliximab and azathioprine in patients with Crohn's disease , 2003, Alimentary pharmacology & therapeutics.
[6] S. Cheung,et al. Mistaken identity: misclassification of TPMT phenotype following blood transfusion. , 2003, European journal of gastroenterology & hepatology.
[7] M. Dubinsky. Monitoring of AZA/6-MP treatment in children with IBD is necessary. , 2003, Inflammatory bowel diseases.
[8] Judy H. Cho,et al. Expression of NOD2 in Paneth cells: a possible link to Crohn’s ileitis , 2003, Gut.
[9] Judy H. Cho,et al. Defining Complex Contributions of NOD2/CARD15 Gene Mutations, Age at Onset, and Tobacco Use On Crohn's Disease Phenotypes , 2003, Inflammatory bowel diseases.
[10] J. Silver. The importance of penetration. , 2003, Inflammatory bowel diseases.
[11] H. Zouali,et al. Association between mutations in the CARD15 (NOD2) gene and Crohn's disease in Israeli Jewish patients , 2003, American journal of medical genetics. Part A.
[12] M. Chamaillard,et al. Nods, Nalps and Naip: intracellular regulators of bacterial‐induced inflammation , 2003, Cellular microbiology.
[13] Changqing Zheng,et al. Progress in searching for susceptibility gene for inflammatory bowel disease by positional cloning. , 2003, World journal of gastroenterology.
[14] D. Jewell,et al. Genotype-phenotype analysis of the Crohn’s disease susceptibility haplotype on chromosome 5q31 , 2003, Gut.
[15] M. Daly,et al. IBD5 is a general risk factor for inflammatory bowel disease: replication of association with Crohn disease and identification of a novel association with ulcerative colitis. , 2003, American journal of human genetics.
[16] S. Davies,et al. Crohn's disease and the NOD2 gene: a role for paneth cells. , 2003, Gastroenterology.
[17] D. Jewell,et al. NOD2/CARD15 gene polymorphisms and Crohn's disease in the Chinese population , 2003, Alimentary pharmacology & therapeutics.
[18] L. Rodrigo,et al. TNF-alpha -308A promoter polymorphism is associated with enhanced TNF-alpha production and inflammatory activity in Crohn's patients with fistulizing disease. , 2003, The American journal of gastroenterology.
[19] J. Satsangi,et al. Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? , 2003, Gut.
[20] J. Belaiche,et al. Early development of stricturing or penetrating pattern in Crohn’s disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype , 2003, Gut.
[21] L. Cardon,et al. Analysis of the IBD5 locus and potential gene-gene interactions in Crohn’s disease , 2003, Gut.
[22] D. Podolsky,et al. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. , 2003, Gastroenterology.
[23] V. Konda,et al. Do inflammatory bowel disease (IBD) patients want genetic testing , 2003 .
[24] P. Rosenstiel,et al. TNF-α and IFN-γ regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells ☆ ☆☆ ★ ★★ ♢ , 2003 .
[25] M. Färkkilä,et al. CARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn’s disease , 2003, Gut.
[26] Tariq Ahmad,et al. Haplotype-specific linkage disequilibrium patterns define the genetic topography of the human MHC. , 2003, Human molecular genetics.
[27] M. Chamaillard,et al. Nod2 Is a General Sensor of Peptidoglycan through Muramyl Dipeptide (MDP) Detection* , 2003, The Journal of Biological Chemistry.
[28] P. McKeigue,et al. Problems of reporting genetic associations with complex outcomes , 2003, The Lancet.
[29] J. Hugot,et al. Gene–environment interaction modulated by allelic heterogeneity in inflammatory diseases , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[30] E. Kuipers,et al. CARD15 and Crohn's Disease: Healthy Homozygous Carriers of the 3020insC Frameshift Mutation , 2003, American Journal of Gastroenterology.
[31] C. O'Morain,et al. Association of NOD2 with Crohn's Disease in a homogenous Irish population , 2003, European Journal of Human Genetics.
[32] S. Foster,et al. Host Recognition of Bacterial Muramyl Dipeptide Mediated through NOD2 , 2003, The Journal of Biological Chemistry.
[33] Min Huang,et al. Interactions of Herbs with Cytochrome P450 , 2003, Drug metabolism reviews.
[34] N. O’Callaghan,et al. CARD15/NOD2 Risk Alleles in the Development of Crohn's Disease in the Australian Population , 2003, Annals of human genetics.
[35] Lucia Mirea,et al. A Population- and Family-Based Study of Canadian Families Reveals Association of HLA DRB1*0103 With Colonic Involvement in Inflammatory Bowel Disease , 2003, Inflammatory bowel diseases.
[36] J. Silver,et al. Variation at NOD2/CARD15 in familial and sporadic cases of Crohn’s disease in the Ashkenazi Jewish population , 2002 .
[37] Yasunori Ogura,et al. Induction of Nod2 in Myelomonocytic and Intestinal Epithelial Cells via Nuclear Factor-κB Activation* , 2002, The Journal of Biological Chemistry.
[38] J. Belaiche,et al. Behaviour of Crohn's disease according to the Vienna classification - Reply , 2002 .
[39] J. Hampe,et al. Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials. , 2002, Pharmacogenetics.
[40] Yusuke Nakamura,et al. Absence of mutation in the NOD2/CARD15 gene among 483 Japanese patients with Crohn's disease , 2002, Journal of Human Genetics.
[41] D. Jewell,et al. Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. , 2002, Gastroenterology.
[42] A. Zinsmeister,et al. N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis. , 2002 .
[43] J. Belaiche,et al. NOD2/CARD15 does not influence response to infliximab in Crohn's disease. , 2002, Gastroenterology.
[44] M. Daly,et al. CARD15 genetic variation in a Quebec population: prevalence, genotype-phenotype relationship, and haplotype structure. , 2002, American journal of human genetics.
[45] A. Macpherson,et al. In siblings with similar genetic susceptibility for inflammatory bowel disease, smokers tend to develop Crohn's disease and non-smokers develop ulcerative colitis , 2002, Gut.
[46] T. Hibi,et al. Lack of common NOD2 variants in Japanese patients with Crohn's disease. , 2002, Gastroenterology.
[47] F. Carbonnel,et al. Long-Term Evolution of Disease Behavior of Crohn's Disease , 2002, Inflammatory bowel diseases.
[48] J. Belaiche,et al. A positive response to infliximab in Crohn disease: Association with a higher systemic inflammation before treatment but not with-308 TNF gene polymorphism , 2002 .
[49] D. Jewell,et al. 60 P The 5q31/IBD5 risk haplotype is associated with overall susceptibility to Crohn's disease and determines perianal phenotype , 2002 .
[50] C. Peterson,et al. Differences Between Children and Adults in Thiopurine Methyltransferase Activity and Metabolite Formation During Thiopurine Therapy: Possible Role of Concomitant Methotrexate , 2002, Therapeutic drug monitoring.
[51] C. Folwaczny,et al. The c-insertion mutation of the NOD2 gene is associated with fistulizing and fibrostenotic phenotypes in Crohn's disease. , 2002, Gastroenterology.
[52] M. Vatn,et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study , 2002, The Lancet.
[53] C. Kelly,et al. P‐Glycoprotein‐170 inhibition significantly reduces cortisol and ciclosporin efflux from human intestinal epithelial cells and T lymphocytes , 2002, Alimentary pharmacology & therapeutics.
[54] R. Myers,et al. Candidate-gene approaches for studying complex genetic traits: practical considerations , 2002, Nature Reviews Genetics.
[55] D. Sachar. Genomics and phenomics in Crohn's disease. , 2002, Gastroenterology.
[56] Alastair Forbes,et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. , 2002, Gastroenterology.
[57] C. O'Morain,et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. , 2002, American journal of human genetics.
[58] S. Targan,et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. , 2002, Gastroenterology.
[59] B. Alizadeh,et al. CARD15 gene and the classification of Crohn's disease , 2002, Immunogenetics.
[60] T. Ahmad,et al. The molecular classification of the clinical manifestations of Crohn's disease. , 2002, Gastroenterology.
[61] G. Novelli,et al. 3020insC mutation within the NOD2 gene in Crohn's disease: frequency and association with clinical pattern in an Italian population. , 2002, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[62] Y. Ogura,et al. Nods: a family of cytosolic proteins that regulate the host response to pathogens. , 2002, Current opinion in microbiology.
[63] J. Belaiche,et al. Inflammatory Bowel Disease A Positive Response to Infliximab in Crohn Disease: Association with a Higher Systemic Inflammation Before Treatment But Not With -308 TNF Gene Polymorphism , 2002, Scandinavian journal of gastroenterology.
[64] J. Belaiche,et al. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease , 2001, Gut.
[65] K. Schulte,et al. Genetic Determinants of IL-6 Expression Levels Do Not Influence Bone Loss in Inflammatory Bowel Disease , 2001, Digestive Diseases and Sciences.
[66] J. Ioannidis,et al. Replication validity of genetic association studies , 2001, Nature Genetics.
[67] Sinead B. O'Leary,et al. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease , 2001, Nature Genetics.
[68] A. Cox,et al. The interleukin 1 receptor antagonist gene allele 2 as a predictor of pouchitis following colectomy and IPAA in ulcerative colitis. , 2001, Gastroenterology.
[69] Judy H. Cho,et al. The Nod2 Gene in Crohn's Disease: Implications for Future Research Into the Genetics and Immunology of Crohn's Disease , 2001, Inflammatory bowel diseases.
[70] F. Carbonnel,et al. Impact of cessation of smoking on the course of ulcerative colitis , 2001, American Journal of Gastroenterology.
[71] S. Fisher,et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations , 2001, The Lancet.
[72] J. Satsangi,et al. The genetics of inflammatory bowel disease , 2001, Alimentary pharmacology & therapeutics.
[73] Mourad Sahbatou,et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease , 2001, Nature.
[74] Judy H. Cho,et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease , 2001, Nature.
[75] T. Bayless,et al. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease , 2001, Gut.
[76] P. Dickman,et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. , 2001, Gastroenterology.
[77] Ann Daly,et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.
[78] N. Camp,et al. Association of the interleukin 1 receptor antagonist gene with ulcerative colitis in Northern European Caucasians , 2001, Gut.
[79] S. Yamaoka,et al. Nod2, a Nod1/Apaf-1 Family Member That Is Restricted to Monocytes and Activates NF-κB* , 2001, The Journal of Biological Chemistry.
[80] D. Weeks,et al. The IBD2 locus shows linkage heterogeneity between ulcerative colitis and Crohn disease. , 2000, American journal of human genetics.
[81] A. Dignass,et al. Genetic factors determine extent of bone loss in inflammatory bowel disease. , 2000, Gastroenterology.
[82] W. Evans,et al. Genetic Polymorphism of Thiopurine S-Methyltransferase: Molecular Mechanisms and Clinical Importance , 2000, Pharmacology.
[83] D. Rubin,et al. Smoking and inflammatory bowel disease. , 2000, European journal of gastroenterology & hepatology.
[84] T. Bayless,et al. Enhanced bioavailability of azathioprine compared to 6‐mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy , 2000, Alimentary pharmacology & therapeutics.
[85] William C. Parks,et al. Secretion of microbicidal α-defensins by intestinal Paneth cells in response to bacteria , 2000, Nature Immunology.
[86] B. Bonaz,et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. , 2000, Gastroenterology.
[87] E S Lander,et al. Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. , 2000, American journal of human genetics.
[88] T. Ashida,et al. Expression of glucocorticoid receptor β in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis ☆ ☆☆ , 2000 .
[89] C. Kumana,et al. Association studies of genetic polymorphisms and complex disease , 2000, The Lancet.
[90] S. Targan,et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. , 2000, Gastroenterology.
[91] S. Targan,et al. HLA class II haplotype associations with inflammatory bowel disease in Jewish (Ashkenazi) and non-Jewish caucasian populations. , 2000, Human immunology.
[92] D. Jewell,et al. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. , 2000, Gastroenterology.
[93] D. Jewell,et al. A Simple Classification of Crohn's Disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998 , 2000, Inflammatory bowel diseases.
[94] P. Keeling,et al. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. , 2000, Gastroenterology.
[95] N J Lynch,et al. Linkage of inflammatory bowel disease to human chromosome 6p. , 1999, American journal of human genetics.
[96] S. Targan,et al. A genome-wide search identifies potential new susceptibility loci for Crohn's disease , 1999 .
[97] Gen Tamiya,et al. Complete sequence and gene map of a human major histocompatibility complex , 1999 .
[98] P. Reitsma,et al. HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis , 1999, Gut.
[99] M. Vatn,et al. Change in the extent of colonoscopic and histological involvement in ulcerative colitis over time. , 1999 .
[100] J. Féher,et al. IL1B gene polymorphisms influence the course and severity of inflammatory bowel disease , 1999, Immunogenetics.
[101] S. Targan,et al. Linkage of Crohn’s disease to the major histocompatibility complex region is detected by multiple non-parametric analyses , 1999, Gut.
[102] A. Peña,et al. Genetic markers in clinically well defined patients with ulcerative colitis (UC) , 1999 .
[103] M. Neurath,et al. Cytokine Gene Transcription By NF‐κB Family Members in Patients with Inflammatory Bowel Disease , 1998 .
[104] A. Ballinger,et al. 6-Mercaptopurine metabolism in Crohn’s disease , 1998, Gut.
[105] P. Barnes,et al. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. , 1998, Clinical science.
[106] H. Steinhart,et al. Reliability of a Crohn's Disease Clinical Classification Scheme Based on Disease Behavior , 1998, Inflammatory bowel diseases.
[107] G. Fakis,et al. Expression of arylamine N-acetyltransferase in human intestine , 1998, Gut.
[108] R. Weinshilboum,et al. Human thiopurine methyltransferase pharmacogenetics. Kindred with a terminal exon splice junction mutation that results in loss of activity. , 1998, The Journal of clinical investigation.
[109] J. Beijnen,et al. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. , 1997, The Journal of clinical investigation.
[110] A. Marshall,et al. Getting the right drug into the right patient , 1997, Nature Biotechnology.
[111] R. Weinshilboum,et al. Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms , 1997, Clinical pharmacology and therapeutics.
[112] J. Satsangi,et al. Genetic markers may predict disease behavior in patients with ulcerative colitis. , 1997, Gastroenterology.
[113] Griffin Jp. The cost of adverse drug reactions. , 1997 .
[114] P. Borst,et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[115] G. Chrousos,et al. Inhibition of mineralocorticoid activity by the β-isoform of the human glucocorticoid receptor , 1997, The Journal of Steroid Biochemistry and Molecular Biology.
[116] J. Terwilliger,et al. Two stage genome–wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12 , 1996, Nature Genetics.
[117] Y. Théorêt,et al. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. , 1996, Gut.
[118] D. Jewell,et al. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease , 1996, The Lancet.
[119] Eric Lander Leonid Kruglyak. Genetic dissection of complex traits , 1996, Nature Genetics.
[120] W. Evans,et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. , 1996, American journal of human genetics.
[121] Jean Weissenbach,et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16 , 1996, Nature.
[122] E. Lander,et al. Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results , 1995, Nature Genetics.
[123] P. Barnes. Anti-inflammatory mechanisms of glucocorticoids. , 1995, Biochemical Society transactions.
[124] W. Evans,et al. Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase. , 1995, Molecular pharmacology.
[125] G. Chrousos,et al. Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. , 1995, The Journal of clinical investigation.
[126] R. Weinshilboum,et al. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. , 1995, British journal of clinical pharmacology.
[127] J. Satsangi,et al. Genetics of inflammatory bowel disease. , 1994, Gut.
[128] G. Gyapay,et al. A second-generation linkage map of the human genome , 1992, Nature.
[129] R. Jorde,et al. The incidence of ulcerative colitis in Northern Norway from 1983 to 1986. The Northern Norwegian Gastroenterology Society. , 1990, Scandinavian journal of gastroenterology.
[130] R. Weinshilboum,et al. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia , 1990, The Lancet.
[131] R. Weinshilboum,et al. Thiopurine pharmacogenetics in leukemia: Correlation of erythrocyte thiopurine methyltransferase activity and 6‐thioguanine nucleotide concentrations , 1987, Clinical pharmacology and therapeutics.
[132] R. Weinshilboum,et al. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. , 1980, American journal of human genetics.
[133] H. Watts,et al. National Cooperative Crohn's Disease Study: extraintestinal manifestations and perianal complications. , 1979, Gastroenterology.
[134] Judy H. Cho,et al. Crohn's disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. , 2003, Gastroenterology.
[135] U. Brinkmann,et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. , 2003, Gastroenterology.
[136] Judy H. Cho,et al. Significant role of genetics in IBD: the NOD2 gene. , 2003, Reviews in gastroenterological disorders.
[137] J. Yamamoto-Furusho,et al. Clinical and genetic heterogeneity in Mexican patients with ulcerative colitis. , 2003, Human immunology.
[138] K. Huse,et al. Haplotype structure and association to Crohn's disease of CARD15 mutations in two ethnically divergent populations , 2003, European Journal of Human Genetics.
[139] J. Hampe,et al. Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab , 2002, The Pharmacogenomics Journal.
[140] A. Forbes,et al. Pharmacogenomics of Response to Anti-Tumor Necrosis Factor Therapy in Patients with Crohn’s Disease , 2002, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.
[141] B. Sikic,et al. Effect of the multidrug resistance modulator valspodar on serum cortisol levels in rabbits , 1998, Cancer Chemotherapy and Pharmacology.
[142] U. Meyer,et al. Molecular mechanisms of genetic polymorphisms of drug metabolism. , 1997, Annual review of pharmacology and toxicology.
[143] J. Lennard-jones,et al. The prognosis of idiopathic proctitis. , 1977, Scandinavian journal of gastroenterology.